{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-007582","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.913310+00:00","generated_at":"2026-06-08T23:48:01.227104+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sunshine Biopharma terminates Adva-27a research agreement with JGH after unfavorable lab results","bullets":["Termination of Research Agreement with Jewish General Hospital effective Dec 2, 2023.","Lab results on Adva-27a molecule were unfavorable, prompting termination.","IND-enabling studies of Adva-27a are paused pending chemical modification review.","Company exploring chemical modification to address suboptimal performance in certain studies.","No financial impact from termination disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-007582","json":"https://secwatch.observer/filing/0001683168-23-007582.json","markdown":"https://secwatch.observer/filing/0001683168-23-007582.md","text":"https://secwatch.observer/filing/0001683168-23-007582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823007582/0001683168-23-007582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823007582/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:48:01.227104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e5c36521cf6587539e116fe6c0dca9495d5182a0","claim":"Sunshine Biopharma Inc. terminated Research Agreement with Jewish General Hospital (JGH) valued at termination of Research Agreement for Adva-27a IND-enabling studies (effective 2023-12-02).","evidence_excerpt":"On November 2, 2023, the Company provided notice to JGH of its termination of the Research Agreement, which will become effective on December 2, 2023, pursuant to the terms of the Research Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823007582/0001683168-23-007582-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Jewish General Hospital (JGH)"},{"label":"Value","value":"termination of Research Agreement for Adva-27a IND-enabling studies"},{"label":"Effective","value":"2023-12-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}